Cytosorbents Corp
Research Cytosorbents Corp (CTSO) on Bullrun: market cap USD 22.31M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCTSO
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Market capUSD 22.31M
- Financial periodQ2 2026
- RevenueUSD 9.63M
- Net income-USD 4.42M
- Free cash flow-USD 635.00K
- Gross margin73.2%
Valuation Snapshot
latest market cap is USD 22.31M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 37.06M | -USD 8.20M | -USD 12.54M | 71.5% | -0.13 | USD 6.25M | USD 16.67M | USD 5.90M |
| FY2024 | USD 35.60M | -USD 20.72M | -USD 14.71M | 69.9% | -0.38 | USD 3.28M | USD 14.00M | USD 11.11M |
| FY2023 | USD 31.08M | -USD 29.25M | -USD 22.19M | 70.6% | -0.65 | USD 14.13M | USD 5.04M | USD 23.48M |
| FY2022 | USD 34.69M | -USD 32.81M | -USD 34.32M | 59.8% | -0.75 | USD 22.14M | USD 5.00M | USD 35.37M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 22.31M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 40.19M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 50.14M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 58.20M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 67.97M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 183.08M | n/a | n/a | n/a |
About Cytosorbents Corp
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Cytosorbents Corp's market cap?
Cytosorbents Corp's market capitalization is USD 22.31M.
What does Cytosorbents Corp do?
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications.